Nextech

Day-to-day investment decisions are led by a partnership group that includes Managing Partners Thilo Schroeder, Rocco Sgobbo, and Kanishka Pothula, alongside Partners Melissa McCracken. Schroeder has been with the firm since 2012 and sits on the boards of multiple portfolio companies including Revolution Medicines and MOMA Therapeutics. Pothula joined in March 2023 from BVF Partners to head the firm's public-markets effort and serves on the boards of Flare Therapeutics, Tango Therapeutics, and Tubulis.

Nextech sources opportunities through a formal network of fourteen science partners — senior academic researchers and clinicians at institutions such as ETH Zurich, Dana-Farber Cancer Institute, Scripps Research, UCSF, and Memorial Sloan Kettering. These science partners provide early visibility into breakthrough research and participate directly in scientific due diligence. The firm's Zurich-Boston-San Francisco footprint also places it within the two most concentrated academic biotech ecosystems globally, creating origination pathways that combine academic insight with access to company formation in U.S. biotech hubs.

Nextech is structured as an asset manager and private equity firm, not a family office. It manages capital on behalf of external limited partners from its base in Zurich, with investment teams in Boston and San Francisco. The firm's investment platform spans multiple funds and, since March 2023, includes a dedicated public-markets effort led by Kanishka Pothula.

Nextech invests directly in private biotechnology companies rather than acting as a fund-of-funds. Its deal structures include venture creation, seed and startup equity, growth-stage rounds, PIPEs, and complex-situation transactions. The addition of a public-markets capability in 2023 allows the firm to invest across both private and public biotech, but there is no indication that Nextech commits as an LP to other venture funds.

Nextech invests across the full company lifecycle in precision oncology, from venture creation and early-stage seed and startup rounds through expansion and late-stage growth, PIPEs, and complex-situation transactions. The common thread is a focus on first- and best-in-class targeted therapies making the transition from scientific validation to value creation. With the launch of a public-markets effort in 2023, the firm can now also hold and trade positions in publicly listed biotech companies.

Chairman Alexis Borisy is a serial biotech entrepreneur who co-founded Foundation Medicine, Blueprint Medicines, Relay Therapeutics, and Tango Therapeutics — several of which became or remain Nextech portfolio investments. Before chairing Nextech, Borisy was a partner at Third Rock Ventures, where he was a founding investor in Editas Medicine, Revolution Medicines, and Magenta Therapeutics, among others. His overlapping founder and investor roles create a dense web of relationships between Nextech and the broader Boston-area precision-medicine cluster.

There is no public disclosure of a philanthropic foundation or charitable vehicle directly affiliated with Nextech. Individual team members have personal philanthropic involvement — Chairman Alexis Borisy chairs the Board of Trustees of the Boston Museum of Science, and Science Partner Rich Heyman is a founding member of Life Science Cares San Diego and Curebound — but these are separate from the firm's investment operations.